SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are, among anti-glycemic drugs, the only class that effectively reduces the risk of cardiovascular death and the occurrence of heart failure in patients with type 2 diabetes [14].